Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas

Terutomo Itoh, Yoshiki Hirooka, Akihiro Itoh, Senju Hashimoto, Hiroki Kawashima, Kazuo Kara, Akira Kanamori, Naoki Omiya, Yasumasa Niwa, Hidemi Goto

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

BACKGROUND: The differentiation of benign from malignant intraductal papillary mucinous tumors (IPMT) is often difficult even by various examination methods. We evaluated the qualitative and quantitative diagnostic ability of contrast-enhanced transabdominal ultrasonography (CE-US), mainly in differentiating benign from malignant tumors in patients with IPMT. PATIENTS: AND METHODS: There were 21 patients with IPMT who underwent CE-US and endoscopic ultrasonography (EUS). Surgery was performed in all 21 patients. Pathological findings were 4 with carcinoma and 17 with adenoma. CE-US was performed using a contrast agent (Levovist; Tanabe, Osaka, Japan) consisting of galactose microbubbles and a small (0.1%) admixture of palmitic acid, and the following items were evaluated by the following procedure. (1) Two reviewers with experienced sonographic and endosonographic ability evaluated CE-US images before and after contrast enhancement and classified the enhancement effects into three grades. In addition, the presence or absence of enhancement effects by CE-US was compared with that of mural nodules visualized by EUS. (2) In all 21 patients, changes in intensity after contrast enhancement were quantitatively measured using an HDI Lab. HDI Lab was provided by ATL (Philips; Bothell, WA) and these software tools rapidly quantify image characteristics within multiple ROI (regions of interest) and make comparisons between several areas or images. In both the early and late phases, the postenhancement intensity, difference between pre- and postenhancement intensity, and the percentage change ((postenhancement value-preenhancement value)/preenhancement value) were compared between malignant and benign lesions, and the ability of CE-US to differentiate between benign and malignant lesions was evaluated in comparison with the ability of EUS to diagnose the degree of malignancy. RESULTS: (1) In both the early and the late phases, both reviewers observed enhancement effects in all 21 patients. And both reviewers observed mural nodules by EUS in all 21 patients. (2) In all 21 patients who underwent resection of IPMT, the intensity increased in both the early and late phases. When the patients with carcinoma were compared with those with adenoma, the postenhancement intensity was significantly higher, and the difference between pre- and postenhancement intensity and the percentage change in the early phase and the late phase was significantly more marked in the carcinoma group (p = 0.019, p = 0.002, p = 0.015, p = 0.012, and p = 0.039, respectively). CONCLUSIONS: CE-US was useful for qualitatively diagnosing tumor lesions in patients with IPMT. Moreover, quantitative changes in intensity can be a parameter for the differential diagnosis of benign and malignant tumors.

Original languageEnglish
Pages (from-to)144-152
Number of pages9
JournalAmerican Journal of Gastroenterology
Volume100
Issue number1
DOIs
Publication statusPublished - 01-01-2005
Externally publishedYes

Fingerprint

Pancreas
Ultrasonography
Endosonography
Neoplasms
Carcinoma
Adenoma
Microbubbles
Palmitic Acid
Galactose
Contrast Media
Japan
Differential Diagnosis
Software

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Itoh, Terutomo ; Hirooka, Yoshiki ; Itoh, Akihiro ; Hashimoto, Senju ; Kawashima, Hiroki ; Kara, Kazuo ; Kanamori, Akira ; Omiya, Naoki ; Niwa, Yasumasa ; Goto, Hidemi. / Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas. In: American Journal of Gastroenterology. 2005 ; Vol. 100, No. 1. pp. 144-152.
@article{f933989789d9482e98933e9306b9f44b,
title = "Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas",
abstract = "BACKGROUND: The differentiation of benign from malignant intraductal papillary mucinous tumors (IPMT) is often difficult even by various examination methods. We evaluated the qualitative and quantitative diagnostic ability of contrast-enhanced transabdominal ultrasonography (CE-US), mainly in differentiating benign from malignant tumors in patients with IPMT. PATIENTS: AND METHODS: There were 21 patients with IPMT who underwent CE-US and endoscopic ultrasonography (EUS). Surgery was performed in all 21 patients. Pathological findings were 4 with carcinoma and 17 with adenoma. CE-US was performed using a contrast agent (Levovist; Tanabe, Osaka, Japan) consisting of galactose microbubbles and a small (0.1{\%}) admixture of palmitic acid, and the following items were evaluated by the following procedure. (1) Two reviewers with experienced sonographic and endosonographic ability evaluated CE-US images before and after contrast enhancement and classified the enhancement effects into three grades. In addition, the presence or absence of enhancement effects by CE-US was compared with that of mural nodules visualized by EUS. (2) In all 21 patients, changes in intensity after contrast enhancement were quantitatively measured using an HDI Lab. HDI Lab was provided by ATL (Philips; Bothell, WA) and these software tools rapidly quantify image characteristics within multiple ROI (regions of interest) and make comparisons between several areas or images. In both the early and late phases, the postenhancement intensity, difference between pre- and postenhancement intensity, and the percentage change ((postenhancement value-preenhancement value)/preenhancement value) were compared between malignant and benign lesions, and the ability of CE-US to differentiate between benign and malignant lesions was evaluated in comparison with the ability of EUS to diagnose the degree of malignancy. RESULTS: (1) In both the early and the late phases, both reviewers observed enhancement effects in all 21 patients. And both reviewers observed mural nodules by EUS in all 21 patients. (2) In all 21 patients who underwent resection of IPMT, the intensity increased in both the early and late phases. When the patients with carcinoma were compared with those with adenoma, the postenhancement intensity was significantly higher, and the difference between pre- and postenhancement intensity and the percentage change in the early phase and the late phase was significantly more marked in the carcinoma group (p = 0.019, p = 0.002, p = 0.015, p = 0.012, and p = 0.039, respectively). CONCLUSIONS: CE-US was useful for qualitatively diagnosing tumor lesions in patients with IPMT. Moreover, quantitative changes in intensity can be a parameter for the differential diagnosis of benign and malignant tumors.",
author = "Terutomo Itoh and Yoshiki Hirooka and Akihiro Itoh and Senju Hashimoto and Hiroki Kawashima and Kazuo Kara and Akira Kanamori and Naoki Omiya and Yasumasa Niwa and Hidemi Goto",
year = "2005",
month = "1",
day = "1",
doi = "10.1111/j.1572-0241.2005.40726.x",
language = "English",
volume = "100",
pages = "144--152",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "1",

}

Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas. / Itoh, Terutomo; Hirooka, Yoshiki; Itoh, Akihiro; Hashimoto, Senju; Kawashima, Hiroki; Kara, Kazuo; Kanamori, Akira; Omiya, Naoki; Niwa, Yasumasa; Goto, Hidemi.

In: American Journal of Gastroenterology, Vol. 100, No. 1, 01.01.2005, p. 144-152.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas

AU - Itoh, Terutomo

AU - Hirooka, Yoshiki

AU - Itoh, Akihiro

AU - Hashimoto, Senju

AU - Kawashima, Hiroki

AU - Kara, Kazuo

AU - Kanamori, Akira

AU - Omiya, Naoki

AU - Niwa, Yasumasa

AU - Goto, Hidemi

PY - 2005/1/1

Y1 - 2005/1/1

N2 - BACKGROUND: The differentiation of benign from malignant intraductal papillary mucinous tumors (IPMT) is often difficult even by various examination methods. We evaluated the qualitative and quantitative diagnostic ability of contrast-enhanced transabdominal ultrasonography (CE-US), mainly in differentiating benign from malignant tumors in patients with IPMT. PATIENTS: AND METHODS: There were 21 patients with IPMT who underwent CE-US and endoscopic ultrasonography (EUS). Surgery was performed in all 21 patients. Pathological findings were 4 with carcinoma and 17 with adenoma. CE-US was performed using a contrast agent (Levovist; Tanabe, Osaka, Japan) consisting of galactose microbubbles and a small (0.1%) admixture of palmitic acid, and the following items were evaluated by the following procedure. (1) Two reviewers with experienced sonographic and endosonographic ability evaluated CE-US images before and after contrast enhancement and classified the enhancement effects into three grades. In addition, the presence or absence of enhancement effects by CE-US was compared with that of mural nodules visualized by EUS. (2) In all 21 patients, changes in intensity after contrast enhancement were quantitatively measured using an HDI Lab. HDI Lab was provided by ATL (Philips; Bothell, WA) and these software tools rapidly quantify image characteristics within multiple ROI (regions of interest) and make comparisons between several areas or images. In both the early and late phases, the postenhancement intensity, difference between pre- and postenhancement intensity, and the percentage change ((postenhancement value-preenhancement value)/preenhancement value) were compared between malignant and benign lesions, and the ability of CE-US to differentiate between benign and malignant lesions was evaluated in comparison with the ability of EUS to diagnose the degree of malignancy. RESULTS: (1) In both the early and the late phases, both reviewers observed enhancement effects in all 21 patients. And both reviewers observed mural nodules by EUS in all 21 patients. (2) In all 21 patients who underwent resection of IPMT, the intensity increased in both the early and late phases. When the patients with carcinoma were compared with those with adenoma, the postenhancement intensity was significantly higher, and the difference between pre- and postenhancement intensity and the percentage change in the early phase and the late phase was significantly more marked in the carcinoma group (p = 0.019, p = 0.002, p = 0.015, p = 0.012, and p = 0.039, respectively). CONCLUSIONS: CE-US was useful for qualitatively diagnosing tumor lesions in patients with IPMT. Moreover, quantitative changes in intensity can be a parameter for the differential diagnosis of benign and malignant tumors.

AB - BACKGROUND: The differentiation of benign from malignant intraductal papillary mucinous tumors (IPMT) is often difficult even by various examination methods. We evaluated the qualitative and quantitative diagnostic ability of contrast-enhanced transabdominal ultrasonography (CE-US), mainly in differentiating benign from malignant tumors in patients with IPMT. PATIENTS: AND METHODS: There were 21 patients with IPMT who underwent CE-US and endoscopic ultrasonography (EUS). Surgery was performed in all 21 patients. Pathological findings were 4 with carcinoma and 17 with adenoma. CE-US was performed using a contrast agent (Levovist; Tanabe, Osaka, Japan) consisting of galactose microbubbles and a small (0.1%) admixture of palmitic acid, and the following items were evaluated by the following procedure. (1) Two reviewers with experienced sonographic and endosonographic ability evaluated CE-US images before and after contrast enhancement and classified the enhancement effects into three grades. In addition, the presence or absence of enhancement effects by CE-US was compared with that of mural nodules visualized by EUS. (2) In all 21 patients, changes in intensity after contrast enhancement were quantitatively measured using an HDI Lab. HDI Lab was provided by ATL (Philips; Bothell, WA) and these software tools rapidly quantify image characteristics within multiple ROI (regions of interest) and make comparisons between several areas or images. In both the early and late phases, the postenhancement intensity, difference between pre- and postenhancement intensity, and the percentage change ((postenhancement value-preenhancement value)/preenhancement value) were compared between malignant and benign lesions, and the ability of CE-US to differentiate between benign and malignant lesions was evaluated in comparison with the ability of EUS to diagnose the degree of malignancy. RESULTS: (1) In both the early and the late phases, both reviewers observed enhancement effects in all 21 patients. And both reviewers observed mural nodules by EUS in all 21 patients. (2) In all 21 patients who underwent resection of IPMT, the intensity increased in both the early and late phases. When the patients with carcinoma were compared with those with adenoma, the postenhancement intensity was significantly higher, and the difference between pre- and postenhancement intensity and the percentage change in the early phase and the late phase was significantly more marked in the carcinoma group (p = 0.019, p = 0.002, p = 0.015, p = 0.012, and p = 0.039, respectively). CONCLUSIONS: CE-US was useful for qualitatively diagnosing tumor lesions in patients with IPMT. Moreover, quantitative changes in intensity can be a parameter for the differential diagnosis of benign and malignant tumors.

UR - http://www.scopus.com/inward/record.url?scp=13744256138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13744256138&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2005.40726.x

DO - 10.1111/j.1572-0241.2005.40726.x

M3 - Article

C2 - 15654794

AN - SCOPUS:13744256138

VL - 100

SP - 144

EP - 152

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 1

ER -